AlloVir approves $100K transaction bonuses for CEO, CFO, GC contingent on 2024 change of control

Kalaris Therapeutics, Inc.

Board approved $100K cash bonuses to CEO Diana Brainard, President/CFO Vikas Sinha, and GC Edward Miller.
Bonuses contingent on Board execution of a definitive change of control agreement in fiscal 2024 and continued employment through closing.
Payments are termed Transaction Bonuses; Brainard and Sinha abstained from voting on their own bonuses.
The bonuses signal active pursuit of a strategic transaction, likely a sale or merger of the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.